{"id":65311,"date":"2026-05-14T15:05:01","date_gmt":"2026-05-14T07:05:01","guid":{"rendered":"https:\/\/flcube.com\/?p=65311"},"modified":"2026-05-14T15:05:02","modified_gmt":"2026-05-14T07:05:02","slug":"novo-nordisks-wegovy-shows-21-6-weight-loss-in-early-responders-oasis-4-subgroup-analysis-reveals-clinically-meaningful-benefits-across-patient-populations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65311","title":{"rendered":"Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders \u2013 OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations"},"content":{"rendered":"\n

Novo Nordisk A\/S<\/strong> (NYSE: NVO<\/a>) presented new subgroup analyses from the Phase III OASIS 4 clinical trial<\/strong> at the European Congress on Obesity 2026 (ECO2026)<\/strong>, demonstrating that Wegovy (semaglutide) tablets<\/strong> deliver substantial weight loss benefits across diverse patient populations, with early responders achieving 21.6% total weight loss<\/strong> by week 64.<\/p>\n\n\n\n

Key Clinical Findings \u2013 Weight Loss Outcomes<\/h2>\n\n\n\n
Patient Subgroup<\/th>Week 16 Weight Loss<\/th>Week 64 Weight Loss<\/th>Population Proportion<\/th><\/tr><\/thead>
Early Responders<\/strong><\/td>13.2%<\/td>21.6%<\/strong><\/td>28.8% of trial population<\/td><\/tr>
Non-Early Responders<\/strong><\/td><10%<\/td>11.5%<\/strong><\/td>71.2% of trial population<\/td><\/tr>
Definition<\/strong><\/td>\u226510% weight loss by week 16<\/td>End of trial (week 64)<\/td>Total trial population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Both subgroups achieved clinically meaningful weight loss<\/strong> by trial conclusion, with even non-early responders reaching the 10%+ threshold widely recognized as clinically significant for obesity management.<\/p>\n\n\n\n

Functional Improvement Analysis \u2013 Physical Function Metrics<\/h2>\n\n\n\n

Patients with Poor Baseline Physical Function:<\/strong><\/p>\n\n\n\n